Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer
Endocrinology · 26.07.2024 · 165 (9)
DOI: 10.1210/endocr/bqae092 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrinology, online erschienen am 23.07.2024. Verfasst von Caroline H Diep und 5 weiteren Autor:innen. Beteiligte Einrichtung: Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA. Hauptthemen laut MEDLINE: Breast Neoplasms, Cancer-Associated Fibroblasts, Receptors, Progesterone, Signal Transduction. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH HHS, Tickle Family Land Grant Endowed Chair in Breast Cancer Research, University of Minnesota University Imaging Centers.
Abstract (Originalsprache)
Breast cancer progression involves intricate interactions between cancer cells and the tumor microenvironment (TME). This study elucidates the critical role of progesterone receptor (PR) signaling in mediating the protumorigenic effects of cancer-associated fibroblasts (CAFs) on estrogen receptor–positive (ER+) luminal breast cancer cells. We demonstrate that CAFs produce physiologically relevant levels of estrogen and progesterone, which significantly contribute to breast cancer tumorigenicity. Specifically, CAF conditioned media (CM) promoted PR-dependent anchorage-independent growth, tumorsphere formation/stem cell expansion, and CD44 upregulation. CAF cells formed co-clusters more frequently with PR+ breast cancer cells relative to PR-null models. While both PR isoforms mediated these actions, PR-A was a dominant driver of tumorsphere formation/stemness, while PR-B induced robust CD44 expression and CAF/tumor cell co-cluster formation. CD44 knockdown impaired CAF/tumor cell co-clustering. Fibroblast growth factor 2 (FGF2), also secreted by CAFs, phosphorylated PR (Ser294) in a MAPK-dependent manner and activated PR to enhance CD44 expression and breast cancer tumorigenicity. The FGF receptor (FGFR) inhibitor PD173074 diminished CAF– and FGF2–dependent PR activation, tumorsphere formation, and co-clustering. In summary, this study reveals a novel mechanism through which stromal CAFs orchestrate elevated PR signaling in ER+ luminal breast cancer via secretion of both progesterone and FGF2, a potent activator of ERK1/2. Understanding tumor cell/TME interactions provides insights into potential therapeutic strategies aimed at disrupting PR– and/or FGF2/FGFR-dependent signaling pathways to prevent early metastasis in patients with ER+ breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Laboratory Medicine and Pathology, University of Minnesota, Minneapolis, MN 55455, USA.
- Department of Medicine, Division of Hematology, Oncology & Transplantation, University of Minnesota, Minneapolis, MN 55455, USA.
ORCID-Profile: Caroline H Diep, Amy R Dwyer, Carol A Lange
Förderung
- NIH HHS
- Tickle Family Land Grant Endowed Chair in Breast Cancer Research
- University of Minnesota University Imaging Centers
- Department of Defense
- NCI NIH HHS
- NIH
Zitieren
APA
Diep, C. H., Spartz, A., Truong, T. H., Dwyer, A. R., El-Ashry, D., & Lange, C. A. (2024). Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer. Endocrinology, 165(9). https://doi.org/10.1210/endocr/bqae092
Vancouver
Diep CH, Spartz A, Truong TH, Dwyer AR, El-Ashry D, Lange CA. Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer. Endocrinology. 2024;165(9). doi:10.1210/endocr/bqae092
BibTeX
@article{Diep2024,
author = {Diep, Caroline H and Spartz, Angela and Truong, Thu H and Dwyer, Amy R and El-Ashry, Dorraya and Lange, Carol A},
title = {Progesterone Receptor Signaling Promotes Cancer Associated Fibroblast Mediated Tumorigenicity in ER+ Breast Cancer},
journal = {Endocrinology},
year = {2024},
volume = {165},
number = {9},
doi = {10.1210/endocr/bqae092}
}
EUVIMED